What are zero-peptide vials, and what is actually in them?

The short answer

Vials sold as peptides are testing with no active ingredient at all — filled instead with hydroxyacetophenone, a cheap ketone. Independent labs disagreed on which isomer for months before comparing data. Separately, the owner of Paradigm Peptides was sentenced to 70 months in federal prison for forged lab certificates and selling testosterone labelled as SARMs.

Evidence tier: Tier 1 for the Paradigm Peptides conviction (US Department of Justice court record); Tier 3 for the zero-peptide findings, which come from independent testing labs and community testers rather than regulatory investigation. Educational content, not medical advice.

The key points:

• "Zero peptide" vials contain no active ingredient — the filler has been identified as hydroxyacetophenone.
• Two labs disagreed on the isomer for months. Janoshik reported the 3-isomer; Chromate identified 4-hydroxyacetophenone (piceol). Janoshik has since corrected its identification.
• A supply-chain link has emerged around outsourced manufacturing, reported by community testers.
• Paradigm Peptides' owner got 70 months — for forged COAs and mislabelled controlled substances, not simply for selling peptides.
• A COA is only as good as the lab and the chain of custody behind it.

What is a "zero peptide" vial?

Evidence tier: 3 — independent lab testing, community-reported.

Exactly what it sounds like: a vial sold as a peptide that, on testing, contains none of the labelled compound. Not underdosed — absent.

Through mid-2026, community testers submitting purchased vials to independent labs began reporting a recurring result across multiple products and vendors. The vials were not empty; they contained a white powder that reconstituted normally and looked unremarkable. It simply was not the peptide on the label.

The substance was eventually identified as hydroxyacetophenone, a cheap aromatic ketone with no therapeutic peptide activity whatsoever. Community shorthand for the phenomenon became "Faketide."

Two things make this worse than ordinary underdosing. A vial containing 60% of its labelled peptide still does something, and a user might reasonably conclude the compound underperformed. A vial containing none of it produces a clean negative — and the user concludes the peptide does not work, when in fact they never took any. And unlike a weak batch, this requires deliberate substitution somewhere in the chain.

Why did the labs disagree, and does it matter?

Evidence tier: 3 — public statements from the labs involved.

This is the most instructive part of the story, and it reflects better on the testing ecosystem than it first appears.

Janoshik identified the counterfeit substance as 3-hydroxyacetophenone. Chromate subsequently challenged that, stating it had identified the compound back in April as piceol — 4-hydroxyacetophenone, CAS 99-93-4 — and that the difference is visible in the UV spectrum: the 4-isomer shows a maximum at 276 nm, the 3-isomer does not. Chromate reported that piceol accounted for roughly 99% of the counterfeit material.

The disagreement was resolved when the labs compared their evidence directly in a public forum. Janoshik acknowledged the misidentification and confirmed the compound as 4-hydroxyacetophenone.

Two lessons follow, and they pull in opposite directions.

The encouraging one: this is how analytical chemistry is supposed to work. A lab published a finding, another lab challenged it with spectral evidence, and the first corrected itself publicly. That is more methodological integrity than much of this industry displays.

The uncomfortable one: it took months. Chromate had the identification in April. The correction came at the end of July. Independent labs in this space were not routinely comparing unusual findings with one another, and in the interval customers were testing vials against a partly wrong reference. Isomer identity does not change the practical answer — either way there is no peptide in the vial — but it matters for tracing the source.

Where is the contamination entering the supply chain?

Evidence tier: 3 — community-reported, not independently verified.

A pattern has been reported, and it points at outsourced manufacturing rather than any single retailer.

One customer testing several products from a vendor found that two tested as zero while the vendor's GHK-Cu products were merely underdosed. The vendor reportedly explained that it had run out of stock and outsourced some production to a third-party facility. Critically, the two products that tested as zero carried a distinct facility marking on the label; the underdosed GHK-Cu did not. Another customer with products bearing the same marking reported the same zero result.

Separately, the supplier ACDC announced a new quality-control policy, stating that the Chinese peptide market had been flooded with counterfeit and inferior raw materials through June and July, and that the problem reached back to the raw-powder suppliers themselves — with some previously reliable suppliers allegedly blending qualified material with inferior stock. ACDC described the issue as particularly serious with HGH.

These are claims by market participants, not regulatory findings, and we cannot verify them independently. But the shape is consistent and worth understanding: the failure appears to be upstream of the vendor you bought from. A retailer with genuinely good intentions and no in-house analytics can pass on counterfeit raw material without knowing.

Vendors' explanations, meanwhile, have grown creative. Reported excuses include the long-standing freight-forwarder substitution claim, contamination attributed to manufacturing pipework, and one vendor attributing unfavourable test results to "human interference or malicious commercial competition."

What actually happened in the Paradigm Peptides case?

Evidence tier: 1 — US Department of Justice court record.

This is where a viral headline and the underlying facts diverge sharply, and the difference matters.

The circulating version was some form of "peptide seller sentenced to six years in prison" — read by many as evidence that selling research peptides is itself what lands people in federal custody.

What the court record shows. Matthew Kawa, owner of Paradigm Peptides, was sentenced to 70 months in federal prison by US District Judge Cristal Brisco in the Northern District of Indiana. He pleaded guilty to selling unapproved drugs and illegally importing them. Between 2019 and 2024 the business sold to more than 54,000 customers across all 50 states and over 80 countries. An Indiana woman was separately sentenced to 16 months.

The conduct behind the sentence:

• Forged laboratory certificates, to lend credibility to the products
• False claims that products were manufactured in the US, when they were imported from China, India and elsewhere
• False purity claims
• Many products sold as SARMs were actually testosterone — a controlled substance — not the compound on the label
• Continued selling after receiving FDA warning letters

The judge described "an incredible trail of harm" and noted that regulators' warnings had been repeatedly ignored.

So the accurate lesson is not "selling peptides gets you imprisoned." It is that forging analytical certificates, misrepresenting manufacturing origin, shipping controlled substances under false labels and ignoring regulators gets you imprisoned. That is a specific set of choices, and it happens to describe precisely the behaviours that make a grey market dangerous to buy from.

What does this mean for anyone buying?

Evidence tier: 3 — practical implications.

Several things follow, and the first is uncomfortable.

A COA is a claim, not a guarantee. The Paradigm case involved forged certificates outright. Separately, the isomer dispute showed that even a genuine lab can publish a wrong identification. A certificate is only worth the independence of the lab, the integrity of the chain of custody, and whether the sample tested has any relationship to the vial you received. Our guide to reading a COA covers what to look for; this episode adds that a COA supplied by the seller is the weakest form of the evidence.

Batch testing beats brand trust. The supply-chain pattern suggests contamination entering via outsourced production, which means a vendor that was reliable last year can ship counterfeit material this year without changing anything about how it presents itself. Reputation is a lagging indicator.

Third-party testing of your own vial is the only direct evidence. It is the reason one of our own community submissions is worth more than most published guidance — a reader had his Semax independently tested and found it at 84% of labelled concentration, which is both a real finding and a demonstration of the only method that actually answers the question.

A "nothing happened" result may not mean the compound failed. If you ran a peptide and felt no effect at all, a zero-content vial is now a live possibility, and it is not distinguishable from a genuine null result without testing.

Limitations

This is educational content, not medical advice.

• The Paradigm Peptides facts come from the DOJ record and court reporting. The zero-peptide findings do not — they come from independent labs and individual testers, and have not been the subject of a regulatory investigation we can cite.
• Claims about specific vendors and suppliers are as reported by market participants, including the companies themselves, and we cannot independently verify them.
• We have not tested any product ourselves. Nothing here should be read as a finding about any specific vendor's current stock.
• The isomer identification was disputed and then corrected. Further revision is possible.
• The scale of the counterfeit problem is unknown. Community testing is self-selected — people test when they suspect something, which inflates the apparent failure rate relative to the whole market.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Two stories broke in the same fortnight and they belong together. In one, vials sold as peptides have been found to contain a cheap ketone and no active ingredient, with the identification disputed between independent labs for months before they compared notes and one publicly corrected itself. In the other, a vendor who sold to 54,000 customers went to federal prison for forging the exact documents that buyers use to reassure themselves.

The common thread is that the verification layer this market runs on — certificates of analysis — is the part being attacked. Forged certificates were central to the criminal case. Genuine certificates were briefly wrong about the counterfeit's identity. And a certificate for a batch is not a certificate for your vial.

None of that means testing is pointless; it means the only test that tells you anything reliable about what you personally injected is one you commissioned yourself, from a lab with no relationship to the seller. That is an expensive and inconvenient conclusion, and it is still the honest one.

The Paradigm sentence is also worth reading correctly rather than as the headline circulated it. The man did not go to prison for selling peptides. He went to prison for forging lab certificates, lying about where products were made, shipping testosterone as SARMs, and continuing after regulators told him to stop. Those are the practices that separate a functioning grey market from a dangerous one, and the case is a reasonably precise map of which behaviours cross the line.

Related on this site

• How to read a peptide COA
• How to verify a peptide vendor
• Spotting counterfeit peptides and fake Ozempic
• Research-grade vs pharmaceutical-grade peptides
• Independent peptide lab testing and heavy metals
• Our vendor trust scores

References

• United States v. Matthew Kawa, Northern District of Indiana — owner of Paradigm Peptides sentenced to 70 months in federal prison; forged laboratory certificates, false US-manufacture claims, products sold as SARMs found to contain testosterone, continued sales after FDA warning letters. More than 54,000 customers, 2019–2024. DOJ · CBS News
• Chromate identification of the counterfeit substance as piceol (4-hydroxyacetophenone, CAS 99-93-4), distinguished from the 3-isomer by UV maximum at 276 nm; reported as ~99% of counterfeit material.
• Janoshik initial identification as 3-hydroxyacetophenone, subsequently corrected to the 4-isomer following direct comparison of spectral evidence.
• ACDC quality-control announcement regarding counterfeit and inferior raw materials in the Chinese supply chain, June–July 2026, reported as particularly affecting HGH.
• Community testing reports linking zero-content results to products bearing a specific outsourced-facility marking.